News & Updates

Continuing enzalutamide after progression improves PFS in mCRPC
Continuing enzalutamide after progression improves PFS in mCRPC
09 Mar 2022 byRoshini Claire Anthony

In patients with metastatic castration-resistant prostate cancer (mCRPC) who experience disease progression while on enzalutamide treatment, continuing enzalutamide appears to improve progression-free survival (PFS), according to results of the phase IIIb PRESIDE trial.

Continuing enzalutamide after progression improves PFS in mCRPC
09 Mar 2022
Use of alternative medicine not uncommon in melanoma patients
Use of alternative medicine not uncommon in melanoma patients
09 Mar 2022

About one in four cutaneous melanoma patients use at least one type of complementary and alternative medicine (CAM), of which herbs and turmeric are the most popular, reveals a prospective study from a tertiary cancer centre in Turkey.

Use of alternative medicine not uncommon in melanoma patients
09 Mar 2022
Point-of-care diagnostics feasible for COVID-19 border testing
Point-of-care diagnostics feasible for COVID-19 border testing
09 Mar 2022